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Summary 
Hepatitis C virus (HCV) is an increasing cause of morbidity and mortality in the United States. Many of the 2.7–3.9 million 
persons living with HCV infection are unaware they are infected and do not receive care (e.g., education, counseling, and medical 
monitoring) and treatment. CDC estimates that although persons born during 1945–1965 comprise an estimated 27% of the 
population, they account for approximately three fourths of all HCV infections in the United States, 73% of HCV-associated 
mortality, and are at greatest risk for hepatocellular carcinoma and other HCV-related liver disease. With the advent of new therapies 
that can halt disease progression and provide a virologic cure (i.e., sustained viral clearance following completion of treatment) in 
most persons, targeted testing and linkage to care for infected persons in this birth cohort is expected to reduce HCV-related morbidity 
and mortality. CDC is augmenting previous recommendations for HCV testing (CDC. Recommendations for prevention 
and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47[No. RR–19]) to 
recommend one-time testing without prior ascertainment of HCV risk for persons born during 1945–1965, a population with 
a disproportionately high prevalence of HCV infection and related disease. Persons identified as having HCV infection should 
receive a brief screening for alcohol use and intervention as clinically indicated, followed by referral to appropriate care for HCV 
infection and related conditions. These recommendations do not replace previous guidelines for HCV testing that are based on 
known risk factors and clinical indications. Rather, they define an additional target population for testing: persons born during 
1945–1965. CDC developed these recommendations with the assistance of a work group representing diverse expertise and 
perspectives. The recommendations are informed by the Grading of Recommendations Assessment, Development, and Evaluation 
(GRADE) framework, an approach that provides guidance and tools to define the research questions, conduct the systematic 
review, assess the overall quality of the evidence, and determine strength of the recommendations. This report is intended to serve 
as a resource for health-care professionals, public health officials, and organizations involved in the development, implementation, 
and evaluation of prevention and clinical services. These recommendations will be reviewed every 5 years and updated to include 
advances in the published evidence. 
Corresponding preparer: Bryce D. Smith, PhD, Division of Viral Hepatitis, 
1600 Clifton Rd, NE, MS G-37, Atlanta, GA 30329. Telephone: 
404-639-6277; Fax: 404-718-8588; E-mail: bsmith6@cdc.gov.
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Introduction 
In the United States, an estimated 2.7–3.9 million persons 
(1.0%–1.5%) are living with hepatitis C virus (HCV) infection 
(1), and an estimated 17,000 persons were newly infected in 
2010, the most recent year that data are available (2). With 
an HCV antibody prevalence of 3.25%, persons born during 
1945–1965 account for approximately three fourths of all 
chronic HCV infections among adults in the United States 
(3). Although effective treatments are available to clear HCV 
infection from the body, most persons with HCV do not 
know they are infected (4–7), do not receive needed care (e.g., 
education, counseling, and medical monitoring), and are not 
evaluated for treatment. HCV testing is the first step toward 
improving health outcomes for persons infected with HCV. 
Since 1998, routine HCV testing has been recommended 
by CDC for persons most likely to be infected with HCV (8) 
(Box). These recommendations were made on the basis of a 
known epidemiologic association between a risk factor and 
acquiring HCV infection. However, many persons with HCV 
infection do not recall or report having any of these specific 
risk factors. 
In a recent analysis of data from a national health survey, 55% 
of persons ever infected with HCV reported an exposure risk 
(e.g., injection-drug use or blood transfusion before July 1992), 
and the remaining 45% reported no known exposure risk 
(CDC, unpublished data, 2012). Other potential exposures 
include ever having received chronic hemodialysis, being born 
to an HCV-infected mother, intranasal drug use, acquiring a 
tattoo in an unregulated establishment, being incarcerated, 
being stuck by a needle (e.g., in health care, emergency 
medical, home, or public safety settings) and receiving invasive 
health-care procedures (i.e., those involving a percutaneous 
exposure, such as surgery before implementation of universal 
precautions). Although HCV is inefficiently transmitted 
Recommendations for the Identification of Chronic 
Hepatitis C Virus Infection Among Persons Born 
during 1945–1965*
•	Adults born during 1945–1965 should receive one-time 
testing for HCV without prior ascertainment of HCV 
risk. 
•	All persons with identified HCV infection should receive 
a brief alcohol screening and intervention as clinically 
indicated, followed by referral to appropriate care and 
treatment services for HCV infection and related 
conditions.  
Guidelines for Prevention and Treatment of 
Opportunistic Infections in HIV-Infected Adults and 
Adolescents† 
•	HIV-infected patients should be tested routinely for 
evidence of chronic HCV infection. Initial testing for 
HCV should be performed using the most sensitive 
immunoassays licensed for detection of antibody to 
HCV (anti-HCV) in blood.
Recommendations for Prevention and Control of 
Hepatitis C Virus (HCV) Infection and HCV-Related 
Chronic Disease§
Routine HCV testing is recommended for 
•	 Persons who ever injected illegal drugs, including those 
who injected once or a few times many years ago and do 
not consider themselves as drug users. 
•	 Persons with selected medical conditions, including 
 – persons who received clotting factor concentrates 
produced before 1987; 
 – persons who were ever on chronic (long-term) 
hemodialysis; and 
 – persons with persistently abnormal alanine 
aminotransferase levels. 
•	 Prior recipients of transfusions or organ transplants, 
including 
 – persons who were notified that they received blood 
from a donor who later tested positive for HCV 
infection; 
 – persons who received a transfusion of blood or blood 
components before July 1992; and 
 – persons who received an organ transplant before 
July 1992.  
Routine HCV testing is recommended for persons with 
recognized exposures, including 
•	Health care, emergency medical, and public safety 
workers after needle sticks, sharps, or mucosal exposures 
to HCV-positive blood. 
•	Children born to HCV-positive women.
BOX. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic diseases
* Source: CDC. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR 2012;61(No. RR–4).
† Source: CDC. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the 
National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009;58(No. RR–4).
§ Source: CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No. RR–19).
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through sexual activity, the prevalence of HCV antibodies 
among persons who report having had ≥20 sex partners is 4.5 
times greater compared with the general population (1). 
These birth-year-based recommendations are intended 
to augment, not replace, the 1998 HCV testing guidelines 
(8). They were developed by the HCV Birth Cohort Testing 
Work Group, which consisted of experts from CDC and 
other federal agencies, professional associations, community-
based organizations, and medical associations. The Work 
Group used the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) framework (9–17) 
to inform the development of these recommendations. The 
GRADE approach provides guidance and tools to define the 
research questions, conduct systematic reviews, assess the 
overall quality of the evidence, and determine the direction 
and strength of the recommendations. Following this evidence 
review, CDC’s Division of Viral Hepatitis (DVH) developed 
this report, which was then peer-reviewed by external experts 
and posted for public comment (www.regulations.gov). CDC 
reviewed and considered all public comments in developing 
the final recommendations. 
Background 
HCV causes acute infection, which can be characterized 
by mild to severe illness but is usually asymptomatic. In 
approximately 75%–85% of persons, HCV persists as a 
chronic infection, placing infected persons at risk for liver 
cirrhosis, hepatocellular carcinoma (HCC), and extrahepatic 
complications that develop over the decades following onset 
of infection (18). 
Because HCV is a bloodborne infection, risks for HCV 
transmission are primarily associated with exposures to 
contaminated blood or blood products (8). In 1998, the highest 
prevalence of antibody to HCV (anti-HCV) was documented 
among persons with substantial or repeated direct percutaneous 
exposures, such as persons who inject drugs (PWID), those 
who received blood from infected donors, and persons with 
hemophilia (60%–90%); moderate rates were found among 
those with repeated direct or unapparent percutaneous 
exposures involving smaller amounts of blood, such as 
hemodialysis patients (10%–30%). Persons with unapparent 
percutaneous or mucosal exposures, including those with 
high-risk sexual behaviors, sexual and household contacts of 
persons with chronic HCV infection (1%–10%), and persons 
with sporadic percutaneous exposures (e.g., health-care workers 
[1%–2%]), had lower rates. According to American Red Cross 
Blood Service systems in the United States, prevalence among 
first time blood donors was even lower (0.16% in 2008) (19). 
Before 1965, the estimated incidence of HCV infection 
(then known as Non A-Non B hepatitis) was low (18 cases 
per 100,000 population). However, the incidence of HCV 
infection increased steadily into the 1980s and remained high 
(130 cases per 100,000 population), representing an average of 
230,000 infections per year during that decade (20). In 1988, 
HCV was identified, and by 1992, sensitive multiantigen 
serologic assays for testing the blood supply had been developed 
and licensed. During 1992–2004, the number of reported 
cases of new HCV infection decreased 78.4% (2), and during 
1999–2008, HCV prevalence among first-time blood donors 
decreased 53%. Much of this decline can be attributed to a 
decrease in cases among PWID (21). Safer injection practices 
among PWID contributed to some of this decline, but the 
downward trend was most likely related to HCV infection 
saturation of the injection-drug-using population (21). A 
smaller proportion of the overall decline in HCV infection 
incidence was attributed to effective screening of blood donors 
to prevent HCV transmission. Since 2004, HCV incidence 
has remained stable (21). In 2010, the estimated number of 
newly acquired (i.e., acute) infections in the United States was 
17,000 (2,22). 
The overall prevalence of anti-HCV in the general population 
of the United States can be estimated by analyzing National 
Health and Nutrition Examination Survey (NHANES) data, 
a representative sample of the civilian noninstitutionalized 
population. NHANES data indicate that HCV infection 
prevalence was 1.6%–1.8% during 1988–2002, consistent with 
the finding that the incidence of infection declined and then 
remained stable during this time (1,20,21,23). Considering 
NHANES data collected from 1999–2008, the anti-HCV 
prevalence estimate is 1.5%, or 3.9 million persons (95% 
confidence interval [CI] = 1.3–1.7; 3.4–4.4 million persons). 
NHANES data underestimate the actual national prevalence 
because these surveys do not include samples of incarcerated or 
homeless persons, populations known to have high prevalence 
of HCV infection. Although no systematic surveys comparable 
to NHANES have sampled these populations, their inclusion 
has been estimated to increase the number of infected persons 
by 500,000–1,000,000 (24). 
Rationale for Augmenting HCV 
Testing Recommendations 
In 1998, recommendations for identifying HCV-infected 
persons were issued as part of a comprehensive strategy for 
the prevention and control of HCV infection and HCV-
related chronic disease (8). HCV testing was recommended 
for persons at high risk for HCV transmission, including 
Recommendations and Reports
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persons who 1) had ever injected drugs, 2) were ever on 
chronic hemodialysis, 3) received blood transfusions or organ 
transplants before July 1992, or 4) received clotting factor 
concentrates produced before 1987 (Box). Screening also was 
recommended for persons who had a recognized exposure (i.e., 
health-care, emergency medical, and public safety workers 
after needle sticks, sharps, or mucosal exposures and children 
born to HCV-infected mothers) and persons with laboratory 
evidence of liver inflammation (i.e., persistently elevated 
alanine aminotransferase levels). In 1999, HCV testing also 
was recommended for persons infected with HIV (25). 
Limited Effectiveness of Current 
Testing Strategies 
Current risk-based testing strategies have had limited success, 
as evidenced by the substantial number of HCV-infected 
persons who remain unaware of their infection (26). Of the 
estimated 2.7–3.9 million persons living with HCV infection 
in the United States, 45%–85% are unaware of their infection 
status (4–7); this proportion varies by setting, risk level in 
the population, and site-specific testing practices. Studies 
indicate that even among high-risk populations for whom 
routine HCV testing is recommended, prevalence of testing 
for HCV seromarkers varies from 17%–87% (4,5); according 
to one study, 72% of persons with a history of injection-drug 
use who are infected with HCV remain unaware of their 
infection status (27). Barriers to testing include inadequate 
health insurance coverage and limited access to regular health 
care (7); however, risk-based testing practices have not been 
successful in identifying most HCV-infected persons, even 
those covered by health insurance (6). 
Barriers exist at the provider level, limiting the success 
of the risk-based approach to HCV testing. Providers lack 
knowledge about hepatitis serology and treatment; studies 
indicate that providers’ level of knowledge regarding HCV 
infection prevalence, natural history, available tests, and testing 
procedures is low (28–30). Although up-to-date professional 
guidelines on HCV testing are available from the American 
Association for the Study of Liver Disease (AASLD) (18,31), 
one survey found that 41.7% of primary care physicians 
reported being unfamiliar with these guidelines (32). In 
addition, accuracy of patient recall of risk behaviors, including 
drug use and sexual encounters, decreases over time (33). 
Increasing HCV-Associated 
Morbidity and Mortality 
HCV-associated disease is the leading indication for 
liver transplantation and a leading cause of HCC in the 
United States (26,34–36). HCC and cirrhosis have been 
increasing among persons infected with HCV (37,38), and 
these outcomes are projected to increase substantially in the 
coming decade (39,40). HCC is the fastest growing cause of 
cancer-related mortality, and infection with HCV accounts for 
approximately 50% of incident HCC (41). A CDC review of 
death certificate data found that the hepatitis C mortality rate 
increased substantially during 1999–2007 (annual mortality 
rate change: +0.18 deaths per 100,000 population per year); in 
2007, HCV caused 15,106 deaths (42). Of the HCV-related 
deaths, 73.4% occurred among persons aged 45–64 years, with 
a median age of death of 57 years (approximately 20 years less 
than the average lifespan of persons living in the United States). 
On the basis of data from prospective and retrospective 
cohorts, an estimated 20% of infected persons will progress 
to cirrhosis 20 years after infection, and up to 5% will die 
from HCV-related liver disease (43). Modeling studies forecast 
substantial increases in morbidity and mortality among persons 
with chronic hepatitis C as they age into their third, fourth, 
and fifth decades living with the disease (44,45). These models 
project that during the next 40–50 years, 1.76 million persons 
with untreated HCV infection will develop cirrhosis, with a 
peak prevalence of 1 million cases occurring from the mid-
2020s through the mid-2030s (40); approximately 400,000 
will develop HCC (40). Of persons with hepatitis C who do 
not receive needed care and treatment, approximately one 
million will die from HCV-related complications (40,46). 
Benefits of HCV Testing and Care 
Clinical preventive services, regular medical monitoring, and 
behavioral changes can improve health outcomes for persons with 
HCV infection. HCV care and treatment recommendations have 
been issued by AASLD and endorsed by the Infectious Disease 
Society of America (IDSA) and the American Gastroenterological 
Association (AGA) (18). Because co-infection with HIV, hepatitis 
A virus (HAV), or hepatis B virus (HBV) and consumption of 
alcohol hasten the progression of HCV-related disease (47), 
professional practice guidelines (18) include counseling to decrease 
or eliminate alcohol consumption and vaccination against HAV 
and HBV for susceptible persons. Additional guidance includes 
counseling and education to reduce interactions between 
herbal supplements and over-the-counter and prescription 
medications (18,31). Because elevated body mass index (BMI) 
(weight [kg]/height [m]2) has been linked to increased disease 
progression among HCV-infected persons, counseling to 
encourage weight loss for persons who have BMI scores ≥25 is 
recommended to reduce the likelihood of insulin resistance and 
disease progression (18,48). As HCV-associated liver disease 
progresses, the likelihood of sustaining a treatment response 
Recommendations and Reports
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decreases (48,49); therefore, early identification, linkage to care, 
and clinical evaluation are critical disease prevention interventions. 
Benefits of HCV Treatment 
AASLD recommends considering antiviral treatment for 
HCV-infected persons with histological signs of bridging 
fibrosis, septal fibrosis, or cirrhosis (18). In 2011, the first 
generation of direct-acting antiviral agents (DAAs), the 
HCV NS3/4A protease inhibitors telaprevir and boceprevir, 
were licensed in the United States for treatment of HCV 
genotype 1(the most common genotype in the United States). 
Compared with conventional pegylated interferon and weight-
based ribavirin therapy (PR) alone, the addition of one of 
these two protease inhibitors in clinical trials increased rates 
of sustained virologic response (SVR) (i.e., viral clearance 
following completion of treatment) from 44% to 75% and 
38% to 63%, respectively, in persons with HCV (50,51). In 
a study of veterans with multiple co-morbidities, achieving an 
SVR after treatment was associated with a substantial reduction 
in risk for all-cause mortality of >50% (52) and substantially 
lower rates of liver-related death and decompensated cirrhosis 
(i.e., cirrhosis with the diagnosis of at least one of the following: 
ascites, variceal bleeding, encephalopathy, or impaired hepatitis 
synthetic function) (18). Because of the recent introduction 
of these treatment regimens, the long-term effects of DAA 
treatment in clinical practice have yet to be established, and the 
benefits might be different in community settings. In addition 
to the new Food and Drug Adminstration (FDA)-approved 
medications, approximately 20 HCV treatments (protease and 
polymerase inhibitors) are undergoing Phase II or Phase III 
clinical trials (53); treatment recommendations are expected 
to change as new medications become available for use in the 
United States. 
Consideration of a New HCV 
Testing Strategy 
Because of the limited effectiveness of risk-based HCV 
testing, the rising HCV-associated morbidity and mortality, 
and advances in HCV care and treatment, CDC has evaluated 
public health strategies to increase the proportion of infected 
persons who know their HCV infection status and are linked 
to care. Several analyses of nationally representative data have 
found a disproportionately high prevalence of HCV infection 
among persons who were born during the mid-1940s through 
the mid-1960s. In an analysis of 1988–1994 NHANES data, 
65% of 2.7 million persons with HCV infection were aged 
30–49 years (23), roughly corresponding to this birth cohort. 
In an analysis of NHANES data during 1999–2002, a similarly 
high proportion of persons with HCV antibody had been born 
during 1945–1964 (Figures 1 and 2) (1). A recent analysis of 
1999–2008 NHANES data found that the prevalence of HCV 
antibody among persons in the 1945–1965 birth cohort was 
3.25% (95% CI = 2.80–3.76); persons born during these years 
accounted for more than three fourths (76.5%) of the total 
anti-HCV prevalence in the United States (3). 
Selection of a Target Birth Cohort 
To select a target birth cohort for an expanded testing 
strategy, CDC considered various birth cohorts with increased 




















FIGURE 1. Prevalence of hepatitis C virus antibody, by age at time of 
survey — National Health and Nutrition Examination Survey, 
United States, 1988–1994 and 1999–2002
Source: Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C 
virus infection in the United States, 1999 through 2002. Ann Internal Med 
2006;144:705–14. Modified and reprinted with permission from Annals of 
Internal Medicine.



















FIGURE 2. Prevalence of hepatitis C virus antibody, by year of birth 
— National Health and Nutrition Examination Survey, United States, 
1988–1994 and 1999–2002
Source: Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C 
virus infection in the United States, 1999 through 2002. Ann Internal Med 
2006;144:705–14. Modified and reprinted with permission from Annals of 
Internal Medicine. 
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determined the weighted, unadjusted anti-
HCV prevalence and the size of the population. 
On the basis of HCV prevalence and 
disease burden, the 1945–1965 birth cohort 
was selected as the target population. Three 
birth cohorts (1945–1965, 1950–1970, 
and 1945–1970) were additionally stratified 
by race/ethnicity and sex (Table 2). The 
differences in the male-to-female ratio 
were not substantial and were not critical 
in selecting the birth cohort. However, the 
difference in prevalence by race/ethnicity 
between the birth cohorts is notable. Both 
the 1950–1970 and 1945–1970 cohorts 
have a lower prevalence of HCV-infected 
non-Hispanic black populations than the 
1945–1965 cohort. Of the 210,000 anti-
HCV-positive persons in the 1945–1949 
cohort, approximately 71,000 (35%) were black. Because 
non-Hispanic black populations account for a substantial 
proportion of the 1945–1965 birth cohort, these birth years 
were included to better address this health disparity. 
When examining the possibility of including persons born 
during 1966–1970 with the target population (i.e., 1945–1965 
cohort), it was determined that such a strategy would direct 
testing to approximately 20 million additional persons at a 
cost of approximately $1.08 billion, resulting in identification 
of an additional 300,000 persons with chronic infection. The 
number needed to screen to avert a single HCV-related death 
was lower in the 1945–1965 birth cohort compared with the 
1945–1970 birth cohort (607 and 679, respectively). Data 
collected through a series of 12 consumer focus groups in 
three different U.S. cities demonstrated that the 1945–1965 
birth cohort is a recognized subpopulation known as the 
“baby boomers;” familiarity with this subpopulation and the 
term used to describe it likely will facilitate adoption of the 
recommendation. On the basis of these assessments, CDC 
selected the 1945–1965 birth cohort as the target population. 
Prevalence of HCV Infection in the 
1945–1965 Birth Cohort 
The prevalence of anti-HCV among persons born during 
1945–1965 is 3.25% (3), five times higher than among adults born 
in other years. The high prevalence of HCV among persons in this 
birth cohort reflects the substantial number of incident infections 
throughout the 1970s and 1980s and the persistence of HCV 
as a chronic infection. Males in this cohort had almost twice the 
prevalence as their female counterparts; HCV infection prevalence 
was highest among non-Hispanic black males (8.12%), followed 
by non-Hispanic white males (4.05%) and Mexican-American 
males (3.41%). 
Complicating health outcomes among HCV-infected 
persons born during 1945–1965 are a lack of health insurance 
(31.5%) and use of alcohol (3). Of all anti-HCV positive 
persons in the 1945–1965 birth cohort who self-reported 
alcohol use, 57.8% reported consuming an average of two or 
more alcoholic drinks per day (3). 
Methods 
CDC employed the GRADE methodology to inform the 
guideline development process. In April 2011, CDC convened 
the HCV Birth Cohort Testing Work Group to explore the 
practicality of developing a recommendation for one-time 
HCV testing for persons unaware of their infection status. 
Epidemiologic data exist to support the consideration of a 
birth year testing strategy; however, the GRADE process 
TABLE 2. Prevalence of anti-HCV among three birth cohorts, by sex 
and race/ethnicity* — National Health and Nutrition Examination 





Male 4.34 4.12 3.89
Female 2.19 2.34 2.14
Race/ethnicity
White, non-Hispanic 2.89 3.01 2.77
Black, non-Hispanic 6.42 5.73 5.60
Mexican American 3.26 2.56 2.71
Abbreviation: anti-HCV = antibody to hepatitis C virus.
* Not adjusted by age or other covariates.
 
TABLE 1. Number and prevalence of persons born during 1945–1970 positive for anti-HCV 
and with chronic HCV infection, by birth cohort — National Health and Nutrition 




Anti-HCV Chronic HCV infection
No.  
(in millions) (Weighted %)†
No.  
(in millions)§ (%)
1945–1965 84.2 2.74 (3.25) 2.06 76.6
1950–1970 89.2 2.89 (3.24) 2.17 80.6
1945–1970 105.1 3.15 (3.00) 2.36 87.3
1950–1965 68.3 2.47 (3.61) 1.85 69.9
1950–1960 45.6 1.83 (4.01) 1.37 52.3
1945–1949 13.2 0.21 (1.58) 0.16 6.7
1966–1970 20.9 0.41 (1.94) 0.30 10.8
Abbreviations: HCV = hepatitis C virus; anti-HCV = antibody to hepatitis C virus.
* Source: U.S. Census Bureau. 2010 Census: Single years of age and sex: summary file 1, table PCT12. 
Available at http://factfinder2.census.gov/faces/tableservices/jsf/pages/productview.
xhtml?pid=DEC_10_SF1_PCT12&prodType=table.  Accessed April 27, 2012. 
† Not adjusted by age or other covariates. 
§ An estimated 75% of anti-HCV–positive persons have chronic HCV infection. (Source: Ghany MG, Strader 
DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and 
treatment of hepatitis C: an update. [Practice Guideline.] Hepatology 2009;49(4):1335–74.)
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dictated that a formal review of the literature be conducted to 
examine the effect that this testing would have on diagnosing 
persons unaware of their HCV infection status, as well as the 
potential benefits and harms that this strategy would have on 
persons tested. The Work Group consisted of 1) a steering 
committee within CDC’s DVH, which led and conducted the 
evidence reviews; 2) representatives from DVH’s Laboratory, 
Prevention, and Epidemiology and Surveillance Branches, 
who were tasked with reviewing and providing input on 
the evidence compiled by the steering committee through 
biweekly meetings; and 3) external (to CDC) representatives, 
who provided input on materials compiled by the steering 
committee through teleconferences, an evidence grading 
methodology training workshop, and a consultation. External 
representatives were selected on the basis of expertise with viral 
hepatitis; members included representatives from hepatitis 
C-related community-based organizations, persons living 
with HCV infection, hepatologists, economists, infectious 
disease specialists, and guideline methodologists. A wide 
range of disciplines, organizations, and geographic regions was 
represented, to include 
•	 federal organizations (Agency for Healthcare Research and 
Quality, National Cancer Institute, Food and Drug 
Administration, Veteran’s Affairs, Health Resources and 
Services Administration, Substance Abuse and Mental 
Health Services Administration, and National Institute of 
Diabetes Digestive and Kidney Diseases), 
•	 professional associations (American Medical Association, 
American College of Physicians, American Academy of Family 
Physicians, Association of Public Health Laboratories, and 
Council of State and Territorial Epidemiologists), 
•	 community-based organizations (Adult Viral Hepatitis 
Prevention Coordinator Program, National Viral Hepatitis 
Roundtable, CopeHealth, National Association of State 
and Territorial AIDS Directors, and Hepatitis Education 
Project), and 
•	 organizations of medical specialists who frequently see patients 
in consultation or referral (AASLD, AGA, and IDSA). 
Several subject matter experts (e.g., hepatologists, economists, 
infectious disease specialists, and guideline methodologists) also 
served as members of the external group. Work Group participants 
were required to disclose conflicts of interest and were notified of 
the restrictions regarding lobbying during the recommendation 
development process (Appendix A). No members’ activities were 
restricted based on the information disclosed. 
Comprehensive systematic reviews of the literature were 
conducted, analyzed, and assessed in two stages to examine the 
availability and quality of the evidence regarding HCV infection 
prevalence and the health benefits and harms associated with 
one-time HCV testing for persons unaware of their status. 
Work Group members communicated through teleconferences 
and attended an in-person workshop on GRADE methodology. 
Initial evidence from the systematic review of the prevalence 
data was shared during the teleconferences, and the target birth 
years were selected. Following that selection, the systematic 
review focused on the HCV-associated morbidity and mortality 
that might be altered by a recommendation for one-time testing 
of persons born during 1945–1965. 
In August 2011, CDC convened a 2-day consultation with 
Work Group members to 1) review and evaluate the quality 
of the evidence for the proposed birth cohort-based strategy, 
2) consider benefits versus harms of patient-important 
outcomes, 3) weigh the variability between the values and 
preferences of HCV testing among potential patients, and 
4) consider resource implications. During the consultation, 
a summary of findings table addressing each patient-
important outcome was presented to consultation attendees 
for discussion (Appendix B). Work Group members later 
provided input on the quality of the evidence and strength of 
the recommendations. Following the consultation, the DVH 
Steering Committee and other DVH representatives reviewed 
the information and reached a decision regarding the strength 
of the recommendations. At that time, a recommendations 
statement and qualifying remarks were developed in accordance 
with GRADE methodology. 
Feedback from the public was solicited through conference 
presentations, meetings with national stakeholders, and public 
comment. Further, the proposed guidelines were peer-reviewed 
by external experts in viral hepatitis. A Federal Register notice 
was released on May 18, 2012, announcing the availability 
of the draft recommendations for public comment through 
June 8, 2012. In addition, external Work Group members 
were asked to comment on the recommendations statement 
and remarks during the public comment process. Feedback 
from the public comment period was reviewed by the DVH 
Steering Committee, and the draft was modified accordingly. 
Throughout the development process, CDC also sought input 
from participants at national conferences, including AASLD’s 
2011 Single Topic Conference, the 2010 Annual Meeting of 
the American Public Health Association, the 2010 AASLD 
Conference, the 2011 Guidelines International Network 
Conference, and Digestive Disease Week 2012. 
GRADE Methodology 
These recommendations were developed using GRADE 
methodology (9–17), which has been adopted by approximately 
60 organizations, including CDC federal advisory committees 
(i.e., the Advisory Committee on Immunization Practices 
and the Healthcare Infection Control Practices Advisory 
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Committee), the World Health Organization, IDSA, AGA, and 
the Cochrane Collaboration (www.gradeworkinggroup.org). 
GRADE provides guidance and tools to define research 
questions, develop an analytic framework, conduct systematic 
reviews, assess the overall quality of the evidence, and determine 
the direction and strength of the recommendations. 
Research questions were formulated to guide the development 
of the recommendations using a population, intervention, 
comparator, and outcome (PICO) format (9). The research 
questions were developed to support a two-stage approach to 
the evidence review: 1) determine the baseline prevalence of 
HCV infection and 2) measure the effects of an intervention 
(i.e., patient-important benefits and harms). 
Per the GRADE process, the HCV Birth Cohort Testing Work 
Group designed an analytic framework (Appendix C), which 
was used to examine patient-important outcomes associated 
with each step of the testing effort, from the identification of 
the target population to the treatment of persons found to be 
infected with HCV. To measure the benefits and harms of HCV 
screening and treatment, patient-important outcomes were 
compiled. These outcomes were ranked, each according to its 
relevance to the recommendation (a rating of 1–3 being of low 
importance; 4–6 being important but not critical to decision 
making; and 7–9 as critical to decision making). Literature 
reviews were conducted on outcomes identified as important 
or critical to decision making. Work Group members had three 
opportunities to rank the outcomes: 1) when the outcomes 
were first identified, 2) after the evidence was presented, and 
3) during the discussion of the benefits and harms, allowing the 
Work Group to weigh the relative importance of the outcomes 
based on the evidence presented and the benefits and harms. 
The quality of the evidence for each patient-important 
outcome was assessed collectively by individual outcome, 
not by individual studies, in the GRADE profiler software 
(GRADEpro 3.6). The quality of the evidence was categorized 
as being “high,” “moderate,” “low,” or “very low” depending on 
the established criteria for rating the quality up or down. The 
quality of evidence for each of the outcomes was rated down if 
it met at least one of the following five criteria: 1) risk of bias; 
2) inconsistency or heterogeneity; 3) indirectness (addressing 
a different population than the one under consideration); 
4) imprecision; or 5) publication bias. Conversely, the quality 
of the evidence was rated up if it met any of three criteria: 
1) large effect size; 2) dose-response; or 3) plausible residual 
confounders (i.e., when biases from a study might be affecting 
the estimated apparent intervention effect) (Appendix B). 
Outcomes were reranked for importance after consideration 
of evidence by the Work Group members. 
The following four factors are considered when determining 
the relevance and strength of a GRADE-based recommendation: 
1) quality of evidence, 2) balance between benefits and harms, 
3) values and preferences, and 4) resource implications. During the 
consultation, the Work Group considered each of these factors in light 
of the evidence presented. A statement based on the direction and 
strength of the recommendation was developed using the GRADE 
criteria; statements were either “for” or “against” an intervention and 
were either strong (designated by a “should” statement) or conditional 
(designated by a “may consider” statement). 
Research Questions 
To facilitate a succinct, systematic review of the evidence, 
the Work Group developed the following review questions to 
be considered when examining prevalence data and patient-
important outcomes: 
•	What is the effect of a birth-year based testing strategy 
versus the standard of care (i.e., risk-based testing) for 
identification of hepatitis C virus (HCV) infection? 
•	 Should HCV testing (versus no testing) be conducted 
among adults at average risk for infection who were born 
during 1945–1965? 
•	Among persons tested and identified with HCV infection, 
is treatment-related SVR (versus treatment failure) 
associated with reduced liver-related morbidity and all-
cause mortality? 
•	 Should HCV testing followed by brief alcohol interventions 
(versus no intervention) be carried out to reduce or cease 
drinking among HCV-infected persons? 
Review questions were aligned with the analytic framework 
and were formed in accordance with PICO. The division of 
these questions into two topics, prevalence data and patient-
important outcomes, reflects the two-stage approach that 
was used to 1) define the testing strategy and birth years of 
interest, and 2) examine the effects of testing persons born 
during 1945–1965 for HCV infection. Because the patient-
important outcomes questions encompass many outcomes, 
they are formed without listing one specific outcome; they 
present only the population, intervention, and comparator. 
Literature Review 
The DVH Steering Committee reviewed current HCV 
testing guidelines (8,18,54–58) and existing scientific evidence; 
systematic reviews and meta-analyses were conducted to 
synthesize the evidence available for the review questions. 
This evidence was compiled and presented to the Work Group 
throughout the development process. 
The systematic review process for these recommendations 
was separated into two stages: 1) a review of HCV infection 
prevalence to determine the effect of a birth-year testing strategy, 
and 2) a review of the effects of testing persons born during 
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1945–1965 on patient-important outcomes. Search strategies 
varied for each stage; however, following the initial collection of 
results from the search, titles and abstracts were reviewed by two 
persons. If disagreement on the inclusion of an article occurred, 
an independent third reviewer decided whether the article would 
be included. For the titles and abstracts that met the inclusion 
criteria, the full article was retrieved and reviewed. Information 
from the full articles was extracted for the GRADE profiles to 
conduct the meta-analyses. 
Prevalence Data 
The review of prevalence data was conducted to identify 
literature addressing a birth-year-based strategy or providing 
additional support for the prevalence estimates (see Selection 
of a Target Birth Cohort). The DVH Steering Committee 
reviewed all literature regarding the effect of a birth-year-based 
testing strategy for HCV infection that had been considered 
and published after CDC’s 1998 recommendation. To be 
selected for review, articles had to have been published during 
1995–2011, describe results of U.S.-based studies, and include 
participants within the target population (i.e., the 1945–1965 
birth cohort). Case studies and studies of persons co-infected 
with HBV or HIV were excluded. Six databases were searched 
for primary research, including grey literature and conference 
abstracts: MEDLINE, EMBASE, Sociological Abstracts, 
Cochrane Library (e.g., Database of Systematic Reviews, 
Central Register of Controlled Trials, and Economic Evaluation 
Database), CINAHL, and Database of Abstracts of Reviews 
of Effects (DARE) (Appendix D). 
Patient-Important Outcomes 
A literature search for the effect of HCV testing and treatment 
on patient-important outcomes was conducted (Appendix E). 
A search of previously published systematic reviews and meta-
analyses was conducted initially and used to address the patient-
important outcomes when available and of high quality. When 
systematic reviews or meta-analyses were unavailable, primary 
studies were sought and added to the results. When possible, 
data from primary studies were entered into systematic review 
software (Review Manager, 2008) to produce meta-analyses 
for estimation of effect sizes. Otherwise, effect size data were 
extracted directly from published meta-analyses. 
 Separate, targeted literature reviews were conducted for 
those outcomes considered important or critical to decision-
making (i.e., given a GRADE rating of ≥4); these outcomes 
included: 
•	 all-cause mortality; 
•	HCC; 
•	 SVR (a marker of virologic cure); 
•	 serious adverse events (SAEs) (i.e., treatment-related side effects); 
•	 quality of life (QoL); 
•	HCV transmission; and 
•	 brief alcohol interventions. 
Systematic reviews for all-cause mortality, SVR, SAEs, 
QoL, HCV, and brief alcohol interventions were conducted 
for literature published in MEDLINE from 1995 through 
July 2011. For HCC, a comprehensive search for HCC was 
conducted for literature published during 1946–2011 in 
MEDLINE, EMBASE, the Cochrane Central Register of 
Controlled Trials, CINAHL, Web of Science, and DARE. 
The selection criteria for the primary literature search 
included intervention studies (i.e., controlled trials, cohort 
studies, and case-control studies) conducted worldwide and 
published in English. Case studies were excluded, along with 
studies of transplant recipients and persons co-infected with 
HBV or HIV, if they were not controlled for in the analysis. To 
be selected, studies needed to present data inclusive of persons 
born during 1945–1965. Because DAAs have only recently 
been licensed, evidence was insufficient on their long-term 
effect on the patient-important outcomes. Therefore, only 
studies providing treatment regimens with pegylated interferon 
(with and without ribavirin) or interferon (with or without 
ribavirin) were examined. 
A systematic, targeted review was conducted to examine 
potential harmful and beneficial patient-important outcomes 
associated with HCV testing and treatment. A similar review 
also was conducted to examine reduction or cessation of alcohol 
use associated with brief interventions provided to persons 
identified as HCV-infected. Only those outcomes considered 
critical to decision making (i.e., all-cause mortality, HCC, 
SVR, treatment-related SAEs, QoL, HCV transmission, and 
alcohol use) were graded on their quality and used to inform 
the strength of the recommendations. 
Results 
Review of HCV Infection Prevalence Data 
Of the 10,619 articles that met the search criteria for the 
HCV infection prevalence review, 31 provided data on HCV 
infection prevalence by birth year (Appendix F). Three of 
those articles (1,23,59) examined nationally representative 
data from NHANES. Because data from population-based 
NHANES is nationally representative, the quality of the 
NHANES data was deemed higher than that from the other 
28 articles. Therefore, NHANES data for 1999–2008 were 
used to determine the most effective birth years to target when 
testing persons for HCV infection. The NHANES analysis 
revealed a 3.25% prevalence of anti-HCV among persons born 
during 1945–1965 (95% CI = 2.80–3.76). The prevalence data 
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were presented to the Work Group early in the development 
process. The results were reviewed again during a discussion 
of patient-important outcomes at the consultation. 
Patient-Important Outcomes 
Of the patient-important outcomes determined by the 
Work Group to be either important or critical for decision 
making (see GRADE Methodology), evidence was found in 
the literature for all-cause mortality, HCC, SVR, SAEs, QoL, 
and alcohol use. However, for several other important or critical 
outcomes (i.e., HCV transmission, insurability, reassurance 
of testing negative, false reassurance of testing negative, and 
worry or anxiety caused by testing true positive), no studies 
examining their importance and relevance to a birth cohort 
recommendation could be identified. With the exception of 
HCV transmission, these outcomes were re-ranked as not 
critical to decision-making. For HCV transmission, the Work 
Group decided to keep the categorization as critical to decision-
making to highlight the need for future research. 
All-Cause Mortality 
Previously published systematic reviews and meta-analyses 
did not provide all-cause mortality information relevant 
to this population, so a systematic review was conducted 
(Appendix G). A total of 22 published articles examined all-
cause mortality among persons tested and treated for HCV 
infection. However, a review of the full articles revealed 
weaknesses in 21 of these studies resulting from insufficient 
sample sizes, unrepresentative study populations, and other 
sources of confounding, thus they did not meet the inclusion 
criteria (Appendix G). One study was identified as directly 
applicable to the target population (52). The study had a large 
sample size and rigorously controlled for covariates in post hoc 
analysis, which improved the Work Group’s confidence in the 
estimate of the effect. This study, which included a sample size 
of 16,864 HCV-infected persons identified through the U.S. 
Department of Veterans Affairs, found that treatment-related 
SVR was associated with a reduction in risk for mortality 
among persons who had HCV infection diagnosed (Relative 
risk [RR] = 0.45; 95% CI = 0.41–0.51). However, this 
study only compares persons who responded to therapy with 
those who did not respond and does not address a screened 
population or an untreated population. Differences in stage 
of liver disease between the groups had the potential to bias 
these findings, but those data were not available. Therefore, the 
confidence in the estimate of effect was deemed to be low, and 
no change in rating of the quality of evidence was performed 
despite a large estimated treatment effect (Appendix B). 
Hepatocellular Carcinoma 
A meta-analysis was conducted to examine HCC as a 
patient-important outcome. A total of 12 observational studies 
(n=25,752) providing adjusted relative risk measures examined 
the incidence of HCC among persons achieving an SVR versus 
those who did not respond to treatment (60–71) (Appendix H, 
Appendix I, Appendix J). Data from these studies revealed 
that treatment-related SVR was associated with a reduced 
risk for HCC (>75%) among persons at all stages of fibrosis 
(RR = 0.24; 95% CI = 0.18–0.31). Minimal heterogeneity was 
reported (I2=22%), mainly attributed to the few occurrences of 
HCC and small sample sizes in the studies. No other criteria 
were fully met to justify downgrading the quality of the 
evidence for this outcome. Instead, the quality of the evidence 
was rated up to moderate because of the substantial measure 
of relative risk (Appendix B). 
Sustained Virologic Response 
Achieving SVR is the first step toward reducing future HCV 
morbidity and mortality. The combination of PR with a DAA 
increases the rate of SVR in treated persons with hepatitis C 
genotype 1 when compared with PR alone. Pooled estimates 
comparing boceprevir- and telaprevir-based regimens with PR 
suggest that these regimens are associated with 28% increases in 
SVR rates (RR = 0.28, 95% CI = 0.24–0.32) (50,51,72–74). 
Although SVR was initially judged by the Work Group 
to be directly associated with patient-important outcomes 
(e.g., reduced viral transmission), further deliberation 
resulted in SVR being defined as an intermediary outcome 
that is predictive of a reduction in morbidity and mortality, 
particularly from HCC. Thus, rating down the quality of the 
evidence for SVR from high to moderate was justified given 
the indirectness of the outcome (Appendix B). 
Treatment-Related Serious Adverse Events 
Treatment for HCV infection with PR can result in serious 
adverse events (SAEs).* In May 2011, triple-drug therapy with 
PR and DAA became the standard of care for patients with 
HCV genotype 1, but limited data are available for systematic 
reviews on SAEs for regimens including these new agents. In 
the telaprevir phase III clinical trial, the most common adverse 
events included gastrointestinal disorders, pruritus, rash, and 
anemia, and 11% of those receiving telaprevir discontinued 
therapy because of SAEs compared with 1% of those receiving 
* Defined by the Food and Drug Administration (FDA) as any undesirable 
experience associated with the use of a medical product in a patient. The event 
is serious and should be reported to FDA when the patient outcome is: death, 
hospitalization, disability or permanent damage, congenital anomaly/birth 
defect, or required intervention to prevent permanent impairment or damage. 
SAEs can include nausea, anemia, rash, and neuropsychiatric disturbances. 
(http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm). 
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PR alone (50). In the boceprevir phase III clinical trial, the most 
common adverse events included fatigue, headache, nausea, and 
anemia. No differences in discontinuation rates between study 
arms were observed (51). The harms of these new treatments 
might be different in community settings. 
Although the addition of boceprevir and telaprevir to standard 
treatment with PR increases the rate of SVR in persons with 
HCV genotype 1, it also has been shown to result in an increased 
rate of adverse events that are severe enough to lead to treatment 
discontinuation (RR = 1.34; 95% CI = 0.95–1.87) (50,51,72–74). 
The quality of the evidence for SAEs was rated down because of 
imprecision and judged to be moderate (Appendix B). 
Quality of Life 
One systematic review was identified that examined the 
effect of HCV testing and treatment on patients’ QoL (75). 
This study included seven observational studies. Although 
analysis of these studies did not yield an effect size, the mean 
QoL associated with the SVR in the intervention group was 
6.6 points higher on the SF-36 Health Survey (a standard tool 
used to measure QoL) (http://www.sf-36.org/tools/sf36.shtml) 
compared with the control group. On the basis of study design 
and the limited evidence available regarding QoL, the quality of 
the evidence for this outcome was rated as low (Appendix B). 
HCV Transmission 
Literature searches were conducted for previously published 
systematic reviews, meta-analyses, and articles that addressed 
HCV transmission. No intervention studies examining the 
effect of HCV testing on the patient-important outcome 
of HCV transmission were identified. However, HCV 
transmission was a critical factor when determining the 
strength of the recommendations, despite the absence of related 
intervention studies. Future research is needed to address this 
gap in knowledge. 
Alcohol Use 
A literature search was conducted for systematic reviews, meta-
analyses, and articles on the effect of an intervention to reduce 
alcohol use among persons found to be infected with HCV. 
Because evidence is limited, the search was broadened to include 
reviews focused on alcohol interventions for persons tested for 
HCV, not just those found positive. Recently, a meta-analysis of 
22 randomized, controlled trials (n=7,619) examined the effects 
of HCV testing followed by a brief alcohol intervention (i.e., an 
assessment of the drinking behaviors of patients and provision 
of brief, one-on-one counseling if the health-care provider 
determines it to be clinically indicated) on drinking behaviors 
versus testing alone (76). The mean reduction of drinking 
alcohol (grams/week) in the intervention groups was 38.42% 
lower (95% CI = 30.91–65.44) than in the control groups after 
follow-up at ≥1 year. The quality of this evidence was initially 
rated as high because it was derived from randomized, controlled 
trials without major risk for bias. However, because the body of 
evidence was not specifically derived from persons with HCV 
infection, the quality of evidence was rated down to moderate 
because of indirectness (Appendix B). 
Factors Considered When 
Determining the Recommendations  
Four factors must be considered when determining the 
relevance and strength of a GRADE-based recommendation: 
quality of evidence, balance between benefits and harms, 
values and preferences, and resource implications. During the 
consultation, the Work Group considered each of these factors 
in light of the evidence presented. 
Determining the Quality of the 
Evidence Across Outcomes Critical for 
Decision Making 
The systematic reviews revealed a lack of evidence directly 
comparing the effectiveness of birth-year based testing to 
risk-based testing. Thus, the Work Group considered available 
evidence from studies examining 1) nationally representative 
observational data on HCV prevalence among varying birth 
cohorts, 2) clinical trial data on the effect of HCV treatment on 
achieving SVR, 3) observational data on the association of SVR 
with HCC and all-cause mortality, and 4) data from a meta-
analysis of randomized controlled trials on the effectiveness of 
brief alcohol interventions in reducing alcohol use. Evidence 
from these studies was reviewed comprehensively to infer 
that birth-year based testing, in combination with alcohol 
reduction interventions, will lead to enhanced identification 
and treatment of the infected population and result in reduced 
morbidity and mortality. 
The GRADE framework follows the principle that the overall 
quality of evidence should be determined based on the lowest 
quality of evidence of any outcome deemed critical for decision 
making. For the proposed HCV testing recommendation, 
critical factors included all-cause mortality, HCC, SVR, and 
SAEs (77). However, two factors were considered when rating 
the overall quality of evidence: 1) the desirable effects of testing 
and treatment (the low quality evidence of mortality reduction 
and the moderate quality evidence of reducing HCC) and 
2) the harms of testing and treatment (the moderate quality 
evidence of adverse events associated with HCV eradication). 
Thus, if the reduction in HCC alone is a sufficiently desirable 
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outcome to support testing and treatment (moderate quality 
evidence), and minimal uncertainty exists regarding the 
effect of the undesirable consequences (i.e., moderate quality 
evidence of SAEs), then the overall quality of evidence 
supporting testing and treatment in this cohort is determined 
to be moderate.
Benefits versus Harms 
A review of published and anecdotal evidence conducted 
in accordance with GRADE methodology indicated that 
the benefits of testing and treating persons with HCV 
infection were greater than the harms. Published evidence was 
predominantly drawn from the summary of findings tables 
(Appendix B) and additional literature shared by the Work 
Group. To supplement that information, anecdotal evidence 
on the benefits and harms associated with several factors was 
considered, including undergoing a liver biopsy, the receipt of 
a false-positive test result, the need to wait or return for test 
results, access to treatment, and the effect of HCV-infection 
notification on insurance and employment. 
Although certain harms (i.e., worry or anxiety while waiting for 
test results, concern about insurability, and occurrence of SAEs 
during treatment) can be uncomfortable for patients, effective 
treatment can result in SVR, which is associated with reductions in 
liver-related morbidity and all-cause mortality. Liver biopsy also can 
result in complications, the most common of which is pain. Other 
less common complications include bleeding, intestinal perforation, 
and death (reported in <0.1% of persons) (78); therefore, the 
benefits associated with HCV treatment were judged to be greater 
than the harms. Additional factors support this judgment. For 
example, concerns about receipt of inaccurate HCV antibody test 
results can be assuaged by the accuracy of HCV RNA testing, and 
the time and resources needed to screen, provide a brief alcohol 
intervention, and refer patients to care is outweighed by the efficacy 
of these interventions in reducing alcohol use. 
Values and Preferences 
Available data are limited regarding the acceptabililty by patients 
of HCV testing in the United States (79). However, this can be 
addressed during physician-patient discussions about individual 
preventive care.  
Resource Implications 
Only two U.S.-based studies specifically examined the cost 
effectiveness and resource implications of birth-year-based 
HCV testing linked to HCV care and treatment; both studies 
found the interventions to be cost effective (46,80). These 
studies, which evaluated slightly different definitions of birth 
cohort, compared birth-cohort testing and treatment with 
the status quo of risk- and medical indication-based testing 
recommendations; both studies demonstrated nearly identical 
cost-effectiveness results. The first study, which defined the 
birth cohort as persons born during 1945–1965, estimated a 
cost per quality-adjusted life year (QALY) gained of $35,700 on 
the basis of a 12-week, response-guided course of telaprevir and 
PR; cost per QALY was an estimated $15,700 when assuming 
treatment with PR alone (46). The second study defined the 
birth cohort as persons born during 1946–1970 and estimated 
a cost per QALY gained of $39,963 for patients treated with 
telaprevir in addition to PR (80). Both modeling studies 
assumed that liver disease progression would not continue for 
those who achieve SVR. 
These cost-effectiveness studies had different assumptions 
about the timing of HCV testing and treatment. The study that 
examined the 1945–1965 birth cohort included all possible 
costs and benefits in a single year (46), whereas the study 
that examined the 1946–1970 birth cohort assumed 20% of 
the eligible population would be screened and treated each 
year for 5 years (46,80). Testing costs (including antibody 
testing, nucleic acid testing of antibody positives, and post-
test counseling) were estimated at $54 per person tested (40). 
The birth-cohort testing strategy will reduce morbidity 
and mortality (Table 3), saving future HCV-related medical 
expenditures. However, in the immediate future, the increase in 
testing and treatment of persons born during 1945–1965 will 
cost more than that associated with current risk-based testing 
and treatment strategies. Several factors contribute to projected 
increases in treatment costs, including an expected increase in 
the number of persons tested and treated for HCV and the 
higher costs associated with combination PR/DAA therapy 
versus PR alone (Table 4). Costs can be compared using four 
different scenarios: risk-based testing with PR therapy; risk-
based testing with PR therapy and DAA; birth-cohort testing 
with PR therapy; and birth-cohort testing with PR therapy 
and DAA, the current standard of care (Table 4). 
To inform cost projections for the birth cohort HCV testing 
strategy, colorectal screening rates were reviewed to estimate 
the testing costs associated with one-time HCV testing for 
persons in the 1945–1965 birth cohort. Both interventions 
focus on screening at a single time point in time (i.e., at 
age 50 years for colorectal screening); therefore, data from 
colorectal screening programs are useful for estimating the 
rate of adoption of a recommendation for one-time prevention 
services. In an analysis of 2005 National Health Interview 
Survey data (a nationally representative household survey), 
19.8% of women and 23.7% of men reported receiving 
colorectal screening during the preceding 3 years (the time 
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since implementation of the United States Preventive Services 
Task Force [USPSTF] screening recommendation) (78,81). 
These percentages were obtained after years of updated 
colorectal screening recommendations and implementation 
of educational campaigns, so they likely are higher than those 
expected to follow adoption of HCV testing recommendations. 
However, adopting the birth-cohort recommendations at the 
same level would result in testing approximately 5.6 million 
women and 6.7 million men for HCV within the first 3 years 
of implementation, at a cost of $664 million; approximately 
400,000 persons with HCV infection would be identified. 
Recommendations 
The following recommendations for HCV testing are 
intended to augment the Recommendations for Prevention and 
Control of Hepatitis C Virus (HCV) Infection and HCV-Related 
Chronic Disease issued by CDC in 1998 (8). In addition to 
testing adults of all ages at risk for HCV 
infection, CDC recommends that: 
•	Adults born during 1945–1965 should 
receive one-time testing for HCV 
without prior ascertainment of HCV risk 
(Strong Recommendation, Moderate 
Quality of Evidence), and 
•	All persons identified with HCV 
infection should receive a brief alcohol 
screening and intervention as clinically 
indicated, followed by referral to 
appropriate care and treatment services 
for HCV infection and related conditions 
(Strong Recommendation, Moderate 
Quality of Evidence). 
Providers and patients can discuss HCV 
testing as part of an individual’s preventive 
health care. For persons identified with 
HCV infection, CDC recommends that 
they receive appropriate care, including 
HCV-directed clinical preventive services 
(e.g., screening for alcohol use, hepatitis A 
and hepatitis B vaccination as appropriate, 
and medical monitoring of disease). 
Recommendations are available to guide 
treatment decisions (31). Treatment 
decisions should be made by the patient and 
provider after several factors are considered, 
including stage of disease, hepatitis C 
genotype, comorbidities, therapy-related 
adverse events, and benefits of treatment. 
Public Health Testing 
Criteria 
HCV testing of persons in the 1945–1965 
birth cohort is consistent with established 
general public health screening criteria 
(82) as evidenced by the following factors: 
1) HCV infection is a substantial health 
TABLE 3. Comparison of risk-based testing with PR treatment strategy and birth cohort 
testing with PR and DAA treatment strategy, by outcome
Outcome 
HCV testing and treatment strategy
Difference
(birth cohort – risk based)
Risk-based
testing* with PR 
therapy
Birth-cohort † 
testing with PR 
and DAA therapy
No. of antibody tests 
administered 
14,793,816 60,404,514 45,610,698 more tests 
conducted
No. of positive results 
delivered to patient
262,260 1,070,840 808,580 more cases 
identified
No. of patients treated 135,089 551,800 416,711 more patients 
treated
No. of patients who achieved a 
sustained viral response 
53,160 310,855 257,695 more patients 
achieved SVRs
No. of patients who ever 
developed compensated 
cirrhosis
994,291 791,053 203,238 cirrhosis cases 
averted
No. of patients who ever 
developed DCC
360,388 286,699 73,689 DCC cases averted
No. of patients who ever 
developed HCC
230,784 183,595 47,189 HCC cases averted
No. of patients who ever 
received a transplant 
75,752 60,268 15,484 transplants averted
No. of HCV-related deaths 591,172 470,293 120,879 deaths averted
Abbreviations: DCC = decompensated cirrhosis; DAA = direct-acting antiviral; HCC = hepatocellular carcinoma; 
HCV = hepatitis C virus; PR = pegylated interferon with ribavirin; SVR = sustained virologic response.
Source: Rein D, Smith BD, Wittenborn JS, Lesesne SB. The cost-effectiveness of birth cohort hepatitis C 
antibody screening in U.S. primary care settings. Ann Intern Med 2012;156:263–70. Modified and reprinted 
with permission from Annals of Internal Medicine. 
* Risk-based testing applies to all persons with an identified risk regardless of year of birth and has been 
the standard of care for HCV screening since 1998.
† Birth-cohort testing applies to all persons born during 1945-1965 regardless of risk.
TABLE 4. Selected medical cost, by HCV testing and treatment strategy — United States, 2012
Medical cost
Testing and treatment strategy
Risk-based testing* 











PR and DAA 
(in millions)
Testing $754 $3,078 $754 $3,078
Treatment $1,508 $6,162 $5,133 $20,662
Total $2,262 $9,240 $5,887 $23,740
Abbreviations: HCV = hepatitis C virus; PR = pegylated interferon plus ribavirin; DAA = direct-acting antivirals.
Source: Rein D, Smith BD, Wittenborn JS, Lesesne SB. The Cost-effectiveness of birth cohort hepatitis C 
antibody screening in U.S. primary care settings. Ann Intern Med 2012;156:263–70. Modified and reprinted 
with permission from Annals of Internal Medicine. 
* Risk-based testing applies to all persons with an identified risk regardless of year of birth and has been 
the standard of care for HCV screening since 1998.
† Birth-cohort testing applies to all persons born during 1945-1965 regardless of risk.
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problem that affects a large number of persons, causes 
negative health outcomes, and can be diagnosed before 
symptoms appear; 2) testing for HCV infection is readily 
available, minimally invasive, and reliable; 3) benefits include 
limiting disease progression and facilitating early access to 
treatments that can save significant life years; and 4) testing is 
cost effective. Such testing would help identify unrecognized 
infections, limit transmission, and help HCV-infected 
persons receive beneficial care and treatment before onset of 
severe HCV-related disease (82). 
Testing Methods 
Hepatitis C Antibody Testing 
Laboratory testing methods for HCV included in these 
recommendations were established by CDC’s Guidelines 
for Laboratory Testing and Result Reporting of Antibody to 
Hepatitis C Virus in 2003 (83). No new methods are introduced 
in these recommendations. HCV testing should be initiated with 
an FDA-approved test for antibody to HCV (anti-HCV). These 
assays are highly sensitive and specific. An HCV point-of-care 
assay that can provide results in <1 hour is available for clinical 
use (84). An immunocompetent person without risks for HCV 
infection who tests anti-HCV negative is not HCV-infected and 
no further testing for HCV is necessary. Additional testing might 
be needed for persons who have ongoing or recent risks for HCV 
exposure (e.g., injection-drug use) and persons who are severely 
immunocompromised (e.g., certain patients with HIV/AIDS or 
those on hemodialysis). 
A person whose anti-HCV test is reactive should be considered to 
either 1) have current HCV infection or 2) have had HCV infection 
in the past that has subsequently resolved (i.e., cleared). To identify 
persons with active HCV infection, persons who initially test anti-
HCV positive should be tested by an HCV nucleic acid test (NAT). 
Hepatitis C Nucleic Acid Testing 
An FDA-approved HCV NAT (also referred to as an 
“HCV RNA test”) should be used to identify active HCV 
infection among persons who have tested anti-HCV positive; 
FDA-approved tests include both quantitative HCV NATs 
(for HCV viral load) and qualitative NATs (for presence or 
absence of viremia). Persons who test anti-HCV positive or 
have indeterminate antibody test results who are also positive 
by HCV NAT should be considered to have active HCV 
infection; these persons need referral for further medical 
evaluation and care. A person who is anti-HCV positive but 
who tests negative by HCV NAT should be considered to not 
have active HCV infection. 
Other HCV-Related Testing Issues 
Quantitative NATs assess the level of viremia in the 
bloodstream expressed as HCV viral load. Although viral load 
is a critical marker for the effectiveness of treatment, it is not 
a reliable indicator of stage of disease. Similarly, liver enzyme 
tests (i.e., alanine aminotransferase [ALT]) reflect the level of 
liver inflammation at the time of the test, but are not correlated 
consistently with the stage of liver disease. ALT levels are 
subject to fluctuations associated with many factors other than 
infection, including BMI and use of alcohol or medication.
Management of Persons Tested for 
HCV Infection 
Communicating Test Results to Persons 
Tested for HCV 
Negative Anti-HCV Test Results 
Persons with negative anti-HCV test results should be 
informed of their test results and reassured that they are 
not infected unless they were recently at risk for infection 
(e.g., current injection-drug use). Repeat testing should be 
considered for persons with ongoing risk behaviors. 
Positive Anti-HCV and Negative HCV RNA 
Test Results 
Persons who are anti-HCV positive but have an HCV RNA-
negative test result should be informed that they do not have 
HCV infection and do not need follow-up testing. 
Positive Anti-HCV and HCV RNA Test Results 
Persons who test positive for both HCV antibody and HCV 
RNA should be informed that they have HCV infection and 
need further medical evaluation for liver disease, ongoing 
medical monitoring, and possible treatment. At the time 
positive test results are communicated to patients, health-care 
providers should evaluate the patient’s level of alcohol use and 
provide a brief alcohol intervention if clinically indicated (see 
Alcohol-use Reduction). Persons with HCV infection also 
should be provided information (either through face-to-face 
sessions, video, or written materials) about 1) HCV infection, 
2) risk factors for disease progression, 3) preventive self-care 
and treatment options, and 4) how to prevent transmission of 
HCV to others. HCV-infected persons also should be informed 
about the resources available to them within their communities, 
including providers of medical evaluation and social support. 
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Post-Test Counseling Messages 
Persons infected with HCV can benefit from the following 
counseling messages. 
•	Contact a health-care provider (either a primary-care 
clinician or specialist [e.g., in hepatology, gastroenterology, 
or infectious disease]), for 
 – medical evaluation of the presence or development of 
chronic liver disease; 
 – advice on possible treatment options and strategies; and 
 – advice on how to monitor liver health, even if treatment 
is not recommended. 
•	 Protect the liver from further harm by, 
 – considering hepatitis A and B vaccination if susceptible 
and if liver disease is present; 
 – reducing or discontinuing alcohol consumption; 
 – avoiding new medicines, including over-the-counter 
and herbal agents (18), without first checking with their 
health-care provider; and 
 – obtaining HIV risk assessment and testing. 
•	 For persons who are overweight (BMI ≥25kg/m2) or obese 
(BMI ≥30kg/m2) (85), 
 – consider weight management or losing weight and 
 – follow a healthy diet and stay physically active. 
•	To minimize the risk for transmission to others, 
 – do not donate blood, tissue, or semen and 
 – do not share appliances that might come into contact 
with blood, such as toothbrushes, dental appliances, 
razors, and nail clippers. 
Alcohol-Use Reduction 
Messages to decrease alcohol use should be provided to 
persons infected with HCV. Alcohol screening and brief 
interventions (SBI) for referral for treatment can reduce the 
number of drinks consumed per week and episodes of binge 
drinking. SBI includes screening patients for excessive alcohol 
consumption, brief counseling for those who screen positive, 
and referral to specialized alcohol treatment for patients with 
possible alcohol dependence. The brief intervention is also an 
opportunity to communicate the HCV-associated risks posed 
by alcohol consumption and provide options for behavioral 
change. The U.S. Preventive Services Task Force (USPSTF) 
recommends screening and behavioral counseling interventions 
to reduce alcohol misuse by adults in primary-care settings 
(86). Screening tools shown to be effective in eliciting a 
history of alcohol use from patients include the Alcohol 
Use Disorders Identification Test (AUDIT). Screening tools 
are available from the National Institute on Alcohol Abuse 
and Alcoholism (http://pubs.niaaa.nih.gov/publications/
Practitioner/CliniciansGuide2005/clinicians_guide.htm), and 
WHO has published intervention tools to help patients adopt 
healthy behaviors regarding alcohol use (http://www.who.int/
substance_abuse/activities/sbi/en/index.html).  
Linkage to Care and Treatment 
Many persons identified as HCV-infected do not receive 
recommended medical evaluation and care after the diagnosis 
of HCV infection (30); this gap in linkage to care can be 
attributed to several factors, including being uninsured or 
underinsured, failure of providers to provide a referral, failure 
of patients to follow up on a referral, drug or alcohol use, and 
other barriers. The lack of such care, or substantial delays 
before care is received, negatively impacts the health outcomes 
of infected persons. Routine testing of persons born during 
1945–1965 is expected to lead to more HCV-infected persons 
being identified earlier in the course of disease. However, to 
improve health outcomes, persons testing positive for HCV 
must be provided with appropriate care and treatment. Linking 
patients to care and treatment is a critical component of the 
strategy to reduce the burden of disease. 
Strategies are needed for HCV-infected persons who are 
experiencing barriers to care. These persons might benefit 
from the replication of effective linkage-to-care models and 
the development of other evidence-based interventions. Active 
linkage-to-care programs provided in a culturally sensitive 
manner (87–89) (e.g., the use of case managers to schedule 
appointments, bring infected patients to doctors’ appointments, 
and follow-up with patients) have been found to be more 
effective (87) than passive referral methods (e.g., providing 
patients with information about the disease and a list of resources 
or referrals to medical care). Such linkage creates opportunities 
for patients to receive information, vaccinations, and prevention 
counseling messages and to more fully engage in care (90). Once 
patients receive care, case management can provide active linkage 
(91–93) to social services (88,94), referral to substance abuse 
services (95–98), and assistance with transportation and housing 
(92,95). Recommendations for the medical management of 
HCV infection and disease are updated regularly by AASLD. 
Notable advances are being made in the care, management, 
and treatment of HCV infection at the time of publication of 
this recommendation. Although primary care clinicians can 
readily provide much of the care necessary for initial evaluation 
and management of persons with HCV infection, antiviral 
treatment is complex, and collaboration between primary-care 
providers and specialists facilitates delivery of optimal care. CDC 
is working with academic and clinical partners and with other 
federal and state agencies to replicate best practices and develop 
new models for HCV care (99). 
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Future Directions 
CDC will conduct demonstration projects to expand access 
to HCV testing and evaluate implementation of HCV testing 
in clinical and public health settings; data from these projects 
will identify best practices. In addition, CDC will employ 
national health surveys (e.g., NHIS) to assess implementation 
of this recommendation at the national level. 
CDC is conducting systematic reviews of other testing and 
prevention recommendations that were included in the 1998 
HCV testing recommendations (3). In addition, CDC will be 
reviewing evidence related to the potential benefits and harms 
of testing persons who were determined to be of “uncertain 
need” in the 1998 recommendations (i.e., those with risks 
that have not been well defined, such as intranasal drug use 
or a history of multiple sex partners). On completion of these 
reviews, recommendations for HCV testing and linkage to care 
will be revised as necessary. The revised guidelines, which will 
incorporate the present birth-cohort-based recommendations 
as well as risk-based strategies, will provide updated, 
comprehensive recommendations for the identification and 
management of HCV infection in the United States.  
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Appendix B
Evidence Tables














Failed or no 
treatment SVR Risk with 




No./N % No./N % RR CI No. CI
SAEs 2,704 
(ref 15–19)





5 Moderate¶ 582/985 (59.1) 493/1,542 (32.0) 0.53 (0.47–0.60) 591 278 fewer (236–313)
Abbreviations: GRADE = Grading of Recommendations, Assessment, Development, and Evaluation; HCV = hepatitis C virus; PR = pegylated interferon plus ribavirin; 
SAEs = serious adverse events; RR = risk ratio; CI = confidence interval; SVR = sustained virologic response.
* Per 1,000 persons receiving HCV treatment.
† Rated down for imprecision. 95% CI includes harms as well as benefits. Sensitivity analysis: excluding one trial (SPRINT 2) that showed a lower discontinuation rate 
in the triple therapy group in one of the treatment arms compared with standard of care, the results would be as follows: RR=1.60 (95% CI = 1.16–2.22) (no imprecision).
§ Failure of viral negativity at 24 weeks post treatment.
¶ Rated down for indirectness. SVR considered an intermediary outcome for long-term benefit.














Failed or no 
treatment SVR Risk with 









1 Low 1,126/9,430 (11.9) 409/7,434 (5.5) 0.7 (0.59–0.83) 119 34 fewer (19–47)
HCC 25,906 
(ref 2–13)
12 Moderate† 145/9,185 (1.6) 1,012/16,721 (6.1) 0.24 (0.18–0.31) 46 23 fewer (21–24)
QoL 5,978 
(ref 14)
7 Low —§ — —§ — — — — 6.6 higher¶ (—)**
Abbreviations: GRADE = Grading of Recommendations, Assessment, Development, and Evaluation; HCV = hepatitis C virus; SVR = sustained virologic response; 
HR = hazard ratio; CI = 95% confidence interval; HCC = hepatocellular carcinoma; QoL = quality of life.
 * Per 1,000 persons tested for HCV infection.
 † Rated up due to large relative risk effect: 0.24; 95% CI = 0.18–0.31.
 § Total number of participants = 5,978; distribution between participants and controls not available.
 ¶ The mean QoL associated with sustained viral response-vitality sub-score in the intervention groups.
 ** 95% CI not provided. Effect was reported as significant. Minimally clinically important difference estimated to be 4.2 (range: 3–5). Effect size results: 0.2; effect sizes 
are classified as small (≤0.2); moderate (0.5); and large (≥0.8 ) (Spiegel BMR, Younossi Z, Hays R, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related 
quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41[4]:790–800.)
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Study event rates Anticipated absolute effects
HCV testing 







Risk with failed or 
no treatment
Mean










22 Moderate 2,922 2,938 313 g alcohol/week* 38.42 g lower (54.16–22.67)
Abbreviations: GRADE = Grading of Recommendations, Assessment, Development, and Evaluation; HCV = hepatitis C virus; CI = 95% confidence interval.
* A total of 21 trials reported baseline alcohol consumption: range: 89–456 g/week; overall mean = 313 g/week (26 standard U.S. drinks [approximately 12 g each] 
per week; average: 3.7 drinks per day).
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Appendix C
Analytic Framework for Guiding HCV Testing 

















Testing persons born 1945–1965 for HCV infection  







Patient Outcomes: Patient Outcomes:Patient Outcomes:
 
• False reassurance 
of testing negative 
(false-negative
results) 
• Reassurance of 
testing negative 
 
• Fewer complications from 
cirrhosis and decompensated 
cirrhosis 
• Fewer liver transplants  
• Fewer incidents of 
hepatocellular carcinoma  
• Less mortality  
• Decreased HCV transmission  
• Higher quality of life
 • More treatment-related
adverse eects 
• More incidents of sustained 
virologic response†
 
• More complications from 
cirrhosis and decompensated 
cirrhosis§
• More liver transplants  
• More incidents of 
hepatocellular carcinoma
• Greater mortality  
• Increased HCV transmission
 • Lower quality of life  
• Fewer treatment-related
serious adverse eects 
• Fewer incidents of sustained 
virologic response †
* Together, these interventions are known as alcohol screening and brief interventions (SBI) for referral for treatment. 
† Viral eradication after treatment completion. 
§ Cirrhosis with the diagnosis of at least one of the following: ascites, variceal bleeding, encephalopathy, or impaired hepatitis synthetic function. 
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Appendix D
Search Strategy for Literature Addressing HCV Prevalence,* by Database
Database† Search terms No. hits No. with abstracts
Cochrane Database 1. (Hepatitis C OR Hep C OR HCV) t.ti,ab,kw Cochrane reviews:32 1,648
Economic evaluations:223
2. Hepatitis C.kw Clinical trials:1,720
CINAHL 1. (MM “Hepatitis C+”) 3,236 647
2. (MH “Hepatitis C+”) 4,503
3. (MH “Antibodies+”) 16,891
4. (MH “Antibodies +”) and (S2 and S3) 304
5. TX prevalence OR frequen* 115,230
6. Cohort* or cross-section* or cross section* 78,023
7. (MH “Epidemiological Research+”# OR #MH “Epidemiology+”#) 217,794
8. (MH “Environment and Public Health (Non-Cinahl)”) 6,696
9. 1 OR 4 3,298
10. 5 OR 6 OR 7 OR 8 339,418
11. (5 OR 6 OR 7 OR 8) and (9 and 10) 793
MEDLINE 1. Hepatitis C [majr] OR Hepatitis C Antibodies [majr] 22,809 6,159
2. 1 AND (Prevalence OR frequen*) 9,134
3. 2 AND (Cohort or cross-sectional OR “cross-sectional” or Epidemiologic 
Studies [mesh])
4,005
EMBASE 1. *Hepatitis C/ or *Hepatitis C Antibody/ 35,963 6,159
2. (prevalence OR frequen*).mp 890,278
3. (cohort OR cross-sectional or “cross adj sectional”).mp 346,055
4. *epidemiology/ 10,345
5. 1 AND (2 OR 3 OR 4) 6,835
Sociological Abstracts 1. Hep C OR hepc or hepatitis C (ti, kw, au, de) —§ 160¶
2. HCV (ti) —
3. 1 OR 2 —
Database of Abstracts of 
Reviews of Effects
1. Explode Hepatitis C 279 171
2. Explode Hepatitis C Antibodies 11
3. Explode Hepatitis C, Chronic 144
4. 1 OR 2 OR 3 280
Abbreviations: HCV = hepatitis C virus. 
* The HCV-prevalence literature search was conducted to determine the effect of a birth-year based testing strategy versus the standard of care (i.e., risk-based 
testing) for identification of HCV infection.
† Search was conducted for literature published during 1995–2011.
§ Unavailable. 
¶ Of these hits, 159 were de-duplicated (i.e., remained after duplicate study reports were identified).
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Appendix E
Search Strategy for Literature* Addressing Patient-Important Outcomes† Associated with 
HCV Testing Among Persons Born During 1945–1965§ 
Outcome Search terms No. hits
All-cause mortality Clinical query 
1. (“hepatitis C” PR HCV) and (mortality) 123
Search
1. Hepatitis C [majr] OR Hepatitis C Antibodies [majr] 33,186
2. mortality 480,636
3. #1 AND #2 1,857
Sustained virologic response Clinical query 
1. (“hepatitis C” OR HCV) AND (“sustained virologic response” or SVR) 127
Search 
1. Hepatitis C [majr] OR Hepatitis C Antibodies [majr] 33,186
2. “sustained virologic response” OR SVR 2,849
3. #1 AND #2 1,607
Serious adverse events Clinical query 
1. ((“hepatitis C” OR HCV) AND (“adverse effects”)) 215
Quality of life Clinical query 
1. ((“hepatitis C” OR HCV) AND (“quality of life”)) 45
HCV transmission Clinical query 
1. ((“hepatitis C” OR HCV) AND (transmission)) 166
Search 
1. Hepatitis C [majr] or Hepatitis C Antibodies [majr] 33,186
2. transmission 207,262
3. #1 AND #2 4,166
Alcohol use Clinical query 
1. ((“hepatitis C” OR HCV) AND (“alcohol use”)) 5
Search 
1. Hepatitis C [majr] OR Hepatitis C Antibodies [majr] 33,186
2. Alcohol use 108,559
3. #1 AND #2 1,018
* Literature searches include all types of publications (e.g., conference abstracts, clinical trials, systematic reviews, and meta-
analyses), whereas clinical queries include only systematic reviews and meta-analyses.
† Although hepatocellular carcinoma (HCC) is considered a patient-important outcome associated with HCV testing, a separate 
search strategy was used for this outcome (see Appendix H). 
§ The search aimed to answer the following questions: 1) Should HCV testing (versus no testing) be conducted among adults at 
average risk for infection who were born during 1945–1965? 2) Among persons tested and identified with HCV infection, is 
treatment-related SVR (versus treatment failure) associated with reduced liver-related morbidity and all-cause mortality? 3) 
Should HCV testing followed by brief alcohol interventions (versus no intervention) be carried out to reduce or cease drinking 
among HCV-infected persons? 
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Appendix G







study reports after 
title and abstract
screening (n = 22)
 
Eligible study reports 




Exclusion of study reports
by title and abstract screening
(n = 1,835)
Exclusion of study reports
by full text screening
(n = 21)
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Eligible study reports 




Exclusion of study reports 
without  abstracts
(n = 1,833)
Exclusion of study reports
by title and abstract screening
(n = 8,329)
Exclusion of study reports
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Appendix H
Search Strategy for Literature Addressing Development of HCC among Persons with HCV 
Who Either Achieve an SVR or Have No Response to Treatment,* by Database
Database Search terms No. hits Dates covered
MEDLINE 1. Hepatitis C[mesh] or “hepatitis c”  
OR “hep c” OR HCV
1. 57,231 1946–02/2012
2. HCC OR hepatocellular 2. 71,033
3. #1 AND #2 3. 6,788
4. Treatment OR therapy OR treat* OR therap* 4. 7,698,358
5. #3 AND #4 5. 3,717
6. Limit 5 to English language 6. 3,238
Total†: 3,275 
De-duplicated§: 3,273
EMBASE (Ovid) 1. (hcc or hepatocellular carcinoma).mp 1. 46,546 1988–02/2012 
2. Limit #1 to English language 2. 38,765 
3. (hepatitis c or hep c or hcv).mp 3. 80,415 
4. #2 and #3 4. 7,359 
5. (treatment or therapy).mp 5. 3,710,093 
6. #4 and #5 6. 3,414
Total†: 3,439 
De-duplicated§: 1,483
Web of Science 1. Topic=(hcc OR hepatocellular) AND topic=(“hepatitis c” OR hep-c OR hcv) 1. 8,352 1950–02/2012 
2. Limit #1 to English language 2. 8,069 
3. Topic=(treatment OR therapy) 3. 2,908,801 
4. #3 AND #2 4. 3,290
Total†: 3,317 
De-duplicated§: 1,421




Cochrane 1. Hepatitis c OR hcv OR hepc OR hepatitis-c OR hep-c Cochrane Reviews: 3 2012








Database of Abstracts 
of Reviews and Effects
1. (hcc OR hepatocellular) AND (hepatitis-c OR hepc OR hep-c OR hepatitis c OR hcv) 1. 152 
De-duplicated§: 107
2012
Abbreviations: HCC = hepatocellular carcinoma; HCV = hepatitis C virus; SVR = sustained viral response. 
* This literature search was conducted to determine the effect of a birth-year-based testing strategy versus the standard of care (i.e., risk-based testing). 
† Search totals were updated in February 2012. 
§ The number of reports remaining after duplicate study reports were identified.
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Appendix I
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• Web of Science: 3,317
 
• DARE: 152 
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Did not meet 
inclusion criteria 
(N = 6,112) 
Full-text articles assessed for eligibility
 
 (N = 309)
 
Full-text articles  
 (N = 30) 
Additional potentially 
eligible study reports
(N = 14) 
 
  
Exclusion of study reports through 




• No SVR/NR data: 114
 
• Editorial/review article: 31
 
• Appropriate outcome not reported: 17
• Did not meet inclusion criteria: 37
 
• Incomplete information: 14
 
Abbreviations: SVR = sustained viral response; NR = non-response.
Recommendations and Reports
MMWR / August 17, 2012 / Vol. 61 / No. 4 31
Appendix J
Meta-analysis of the Effects of Treatment Response on 
Incidence of Hepatocellular Carcinoma
Abbreviations: CI = 95% confidence interval; HR = hazard ratio; SE = standard error; SVR = sustained virologic response; NR = non-response; IV = inverse variance.
* Heterogeneity: Tau2 = 0.04; Chi2 = 14.05; degrees of freedom = 11 (P=0.23); I2 = 22%; test for overall effect: Z = 10.80 (P<0.00001).
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